Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLTNYSEMKT:PHGENASDAQ:SKYEOTCMKTS:VICP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.46+15.7%$0.44$0.30▼$10.62$65.49M23.23 million shs2.40 million shsPHGEBiomX$0.53-28.4%$0.57$0.48▼$4.90$12.90M1.5179,421 shs53,300 shsSKYESkye Bioscience$2.05+13.3%$1.72$1.14▼$13.44$63.50M1.74533,558 shs245,400 shsVICPVicapsys Life Sciences$1.77$1.88$1.25▼$3.00$57.30M-4.03250 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%-13.18%+7.56%-33.24%-90.90%PHGEBiomX0.00%-1.04%+4.40%-36.92%-83.95%SKYESkye Bioscience0.00%-15.39%+34.89%-44.55%-83.20%VICPVicapsys Life Sciences0.00%0.00%0.00%-13.66%+298.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics3.8937 of 5 stars3.32.00.04.71.62.50.6PHGEBiomX1.5562 of 5 stars3.50.00.00.00.00.81.3SKYESkye Bioscience1.4277 of 5 stars3.51.00.00.03.40.00.0VICPVicapsys Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,218.63% UpsidePHGEBiomX 3.00Buy$23.004,247.83% UpsideSKYESkye Bioscience 3.00Buy$16.60709.76% UpsideVICPVicapsys Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHGE, APLT, SKYE, and VICP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$455K143.94N/AN/A($0.20) per share-2.31PHGEBiomXN/AN/AN/AN/A$0.70 per shareN/ASKYESkye BioscienceN/AN/AN/AN/A($0.17) per shareN/AVICPVicapsys Life SciencesN/AN/AN/AN/A($0.06) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$0.95N/AN/AN/AN/A-260.75%-76.04%N/APHGEBiomX-$28.32M-$3.32N/AN/AN/AN/A-127.82%-56.50%N/ASKYESkye Bioscience-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/AVICPVicapsys Life Sciences-$1.18M-$0.04N/A∞N/AN/AN/A-3,906.36%N/ALatest PHGE, APLT, SKYE, and VICP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/AVICPVicapsys Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.061.06PHGEBiomX0.512.842.84SKYESkye BioscienceN/A14.1914.19VICPVicapsys Life SciencesN/A0.030.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%PHGEBiomX40.57%SKYESkye Bioscience21.09%VICPVicapsys Life SciencesN/AInsider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics8.60%PHGEBiomX1.17%SKYESkye Bioscience4.50%VICPVicapsys Life Sciences5.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30141.58 million106.35 millionOptionablePHGEBiomX12025.00 million44.04 millionNot OptionableSKYESkye Bioscience1130.98 million29.43 millionOptionableVICPVicapsys Life Sciences232.37 million30.44 millionNot OptionablePHGE, APLT, SKYE, and VICP HeadlinesRecent News About These CompaniesBritish Science Week - Teaching ResourcesNovember 6, 2024 | bbc.co.ukBest term life insurance: Expert-rated in April 2024April 28, 2024 | usatoday.comScanning Electron Microscopy for the Life SciencesApril 20, 2024 | cambridge.orgEY Life SciencesApril 8, 2024 | pmlive.comLife ScienceJanuary 30, 2024 | dmagazine.comCaris Life SciencesNovember 30, 2023 | dmagazine.comAnavex Life Sciences Corp AVXLNovember 4, 2023 | morningstar.comVICP - Vicapsys Life Sciences, Inc.August 9, 2023 | finance.yahoo.comViCapsys files for Nasdaq uplisting, $8M public offeringJuly 3, 2023 | msn.comLife sciences sector to get £650m boost in new Government funding packageJune 9, 2023 | aol.co.uk‘Not Seeing Any Activity At All’: Once-Hot Life Sciences Leasing Market FreezesApril 1, 2023 | bisnow.comThe Science of LifeMarch 29, 2023 | nature.comThe ultimate list of leaders in life sciences.March 16, 2023 | statnews.comDefining life and personhood: What science, philosophy, and religion have to sayMarch 13, 2023 | kcrw.comLife Sciences Innovator Category Winner 2023February 23, 2023 | news-medical.netGlobal law firm Goodwin is setting up a Philly tech, startups and life sciences practiceFebruary 21, 2023 | technical.lyGlobal Life Science Tools Strategic Business Report 2023: Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market ProspectsFebruary 19, 2023 | benzinga.comFocused exclusively on life sciences, three top investors set out on their ownJanuary 28, 2023 | statnews.comTop risks for life sciences sector revealed – reportJanuary 15, 2023 | canadianlawyermag.comHouston On Track As Future Life Sciences Powerhouse, But Everyone Needs To Mind The Gaps FirstJanuary 15, 2023 | bisnow.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHGE, APLT, SKYE, and VICP Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.46 +0.06 (+15.74%) Closing price 04:00 PM EasternExtended Trading$0.46 0.00 (-0.78%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.BiomX NYSEMKT:PHGE$0.53 -0.21 (-28.42%) Closing price 03:31 PM EasternExtended Trading$0.54 +0.01 (+1.32%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Skye Bioscience NASDAQ:SKYE$2.05 +0.24 (+13.26%) Closing price 04:00 PM EasternExtended Trading$1.98 -0.07 (-3.41%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Vicapsys Life Sciences OTCMKTS:VICP$1.77 0.00 (0.00%) As of 05/9/2025Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
